A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
Completed · Phase 1
Conditions studied: Chronic Hepatitis D Infection
In brief
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.
Key facts
- Study ID
- NCT05760300
- Run by
- Gilead Sciences
- People needed
- 41
- Starts
- 2023-03-15
- Expected to finish
- 2024-07-23
- Last updated by the study team
- 2025-09-18
Who can join
Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.
Where it is running
- Velocity Clinical Research, New Smyrna Beach — Edgewater, Florida, United States
- Clinical Pharmacology of Miami, LLC — Miami, Florida, United States
- Advanced Pharma CR, LLC — Miami, Florida, United States
- Panax Clinical Research — Miami Lakes, Florida, United States
- Floridian Clinical Research, LLC — Miami Lakes, Florida, United States
- Global Clinical Professionals Research — St. Petersburg, Florida, United States
- Genesis Clinical Research, LLC — Tampa, Florida, United States
- Massachusetts General Hospital - Renal Associates Clinic — Boston, Massachusetts, United States
- Nucleus Network — Saint Paul, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.